journal article·2023-01-10

Amplified Fenton-Based Oxidative Stress Utilizing Ultraviolet Upconversion Luminescence-Fueled Nanoreactors for Apoptosis-Strengthened Ferroptosis Anticancer Therapy

Nguyen Thi Nguyen, Juho Kim, Xuan Thien Le, Woo Tak Lee, Eun Seong Lee, Kyung Taek Oh, Han-Gon Choi, Yu Seok Youn

ACS Nano· Volume 17· Issue 1
Publisher page

Abstract

As an emerging anticancer strategy, ferroptosis has recently been developed in combination with current therapeutic modalities to overcome the existing limitations of conventional therapies. Herein, an ultraviolet (UV) upconversion luminescence-fueled nanoreactor is explored to combine ferroptosis and apoptosis through the UV-catalyzed Fenton reaction of an iron supplement (ferric ammonium citrate) loaded in a mesoporous silica layer in addition to the support of a chemotherapeutic agent (cisplatin) attached on the functionalized silica surface for the treatment of triple negative breast cancer (TNBC). The nanoplatform can circumvent the low penetration depth typical of UV light by upconverting near-infrared irradiation and emitting UV photons that convert Fe3+ to Fe2+ to boost the generation of hydroxyl radicals (·OH), causing devastating lipid peroxidation. Apart from DNA damage-induced apoptosis, cisplatin can also catalyze Fenton-based therapy by its abundant production of hydrogen peroxide (H2O2). As a bioinspired lipid membrane, the folate receptor-targeted liposome as the coating layer offers high biocompatibility and colloidal stability for the upconversion nanoparticles, in addition to prevention of the premature release of encapsulated hydrophilic compounds, before driving the nanoformulation to the target tumor site. As a result, superior antitumor efficacy has been observed in a 4T1 tumor-bearing mouse model with negligible side effects, suggesting that such a nanoformulation could play a pivotal role in effective apoptosis-strengthened ferroptosis TNBC therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do 16419, Republic of Korea

Department of Biotechnology and Department of Biomedical-Chemical Engineering, The Catholic University of Korea, 43 Jibong-ro, Bucheon-si, Gyeonggi-do 14662, Republic of Korea

College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea

College of Pharmacy, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan 15588, Republic of Korea

Funding

National Research Foundation of Korea

References (81)

Show source-provided references
1. 10.3322/caac.2007310.3322/caac.20073 ↗
2. 10.1016/j.addr.2009.05.00610.1016/j.addr.2009.05.006 ↗
3. 10.1158/0008-5472.CAN-16-153610.1158/0008-5472.CAN-16-1536 ↗
4. 10.7497/j.issn.2095-3941.2015.003010.7497/j.issn.2095-3941.2015.0030 ↗
5. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
6. 10.1016/S0926-3373(01)00281-810.1016/S0926-3373(01)00281-8 ↗
7. 10.1080/1064338050032656410.1080/10643380500326564 ↗
8. 10.1016/S0043-1354(00)00342-010.1016/S0043-1354(00)00342-0 ↗
9. 10.1016/j.cbi.2005.12.00910.1016/j.cbi.2005.12.009 ↗
10. 10.1021/nn403080y10.1021/nn403080y ↗
11. 10.1021/ja072918x10.1021/ja072918x ↗
12. 10.1039/C5PY01742D10.1039/C5PY01742D ↗
13. 10.1021/ja807087z10.1021/ja807087z ↗
14. 10.1080/1476417050034457510.1080/14764170500344575 ↗
15. 10.1021/cr030707e10.1021/cr030707e ↗
16. 10.1021/acs.nanolett.0c0050210.1021/acs.nanolett.0c00502 ↗
17. 10.1016/j.cej.2021.12955710.1016/j.cej.2021.129557 ↗
18. 10.1038/s41467-021-26655-410.1038/s41467-021-26655-4 ↗
19. 10.1021/acsnano.8b0560210.1021/acsnano.8b05602 ↗
20. 10.2174/156652401366613111112213310.2174/1566524013666131111122133 ↗
21. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
22. 10.1002/smll.20150211910.1002/smll.201502119 ↗
23. 10.1007/s40005-021-00553-910.1007/s40005-021-00553-9 ↗
24. 10.1021/acsnano.8b0616410.1021/acsnano.8b06164 ↗
25. 10.1021/acsnano.5b0778110.1021/acsnano.5b07781 ↗
26. 10.1007/s11426-021-1126-x10.1007/s11426-021-1126-x ↗
27. 10.1002/adfm.20130213310.1002/adfm.201302133 ↗
28. 10.1021/acs.jpcc.8b0937110.1021/acs.jpcc.8b09371 ↗
29. 10.1016/j.addr.2012.05.00710.1016/j.addr.2012.05.007 ↗
30. 10.1039/b809132n10.1039/b809132n ↗
31. 10.1021/jacs.7b0022310.1021/jacs.7b00223 ↗
32. 10.3762/bjnano.10.23110.3762/bjnano.10.231 ↗
33. 10.1021/acs.accounts.5b0007810.1021/acs.accounts.5b00078 ↗
34. 10.1016/j.ceramint.2013.02.08410.1016/j.ceramint.2013.02.084 ↗
35. 10.1021/acs.nanolett.0c0312710.1021/acs.nanolett.0c03127 ↗
36. 10.1088/0022-3727/44/7/07500310.1088/0022-3727/44/7/075003 ↗
37. 10.1021/nn901403210.1021/nn9014032 ↗
38. 10.1029/93JD0020210.1029/93JD00202 ↗
39. 10.1517/17425247.5.3.30910.1517/17425247.5.3.309 ↗
40. 10.3402/nano.v3i0.1849610.3402/nano.v3i0.18496 ↗
41. 10.1007/s40005-022-00559-x10.1007/s40005-022-00559-x ↗
42. 10.1038/s41571-020-0339-510.1038/s41571-020-0339-5 ↗
43. 10.1039/C5NR01833A10.1039/C5NR01833A ↗
44. 10.1021/mp500389v10.1021/mp500389v ↗
45. 10.1007/s11095-022-03178-110.1007/s11095-022-03178-1 ↗
46. 10.1007/s40005-022-00573-z10.1007/s40005-022-00573-z ↗
47. 10.1021/acsami.8b0040910.1021/acsami.8b00409 ↗
48. 10.1006/bbrc.1997.796210.1006/bbrc.1997.7962 ↗
49. 10.3892/ol.2017.713410.3892/ol.2017.7134 ↗
50. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
51. 10.1016/j.ymthe.2021.03.02210.1016/j.ymthe.2021.03.022 ↗
52. 10.3791/6068210.3791/60682 ↗
53. 10.1038/s41556-020-0565-110.1038/s41556-020-0565-1 ↗
54. 10.1039/c2ra20816d10.1039/c2ra20816d ↗
55. 10.1038/s41419-021-03613-y10.1038/s41419-021-03613-y ↗
56. 10.1016/j.freeradbiomed.2020.02.02710.1016/j.freeradbiomed.2020.02.027 ↗
57. 10.1186/1550-2783-2-2-3810.1186/1550-2783-2-2-38 ↗
58. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
59. 10.4143/crt.2016.57210.4143/crt.2016.572 ↗
60. 10.1038/cddis.2014.46510.1038/cddis.2014.465 ↗
61. 10.1021/jm900138u10.1021/jm900138u ↗
62. 10.1038/sj.onc.120301510.1038/sj.onc.1203015 ↗
63. 10.1038/sj.cdd.440110910.1038/sj.cdd.4401109 ↗
64. 10.1038/cdd.2017.17110.1038/cdd.2017.171 ↗
65. 10.1016/j.biomaterials.2015.08.03110.1016/j.biomaterials.2015.08.031 ↗
66. 10.1038/ncomms467210.1038/ncomms4672 ↗
67. 10.1126/sciadv.aax134610.1126/sciadv.aax1346 ↗
68. 10.1016/j.molcel.2018.10.04210.1016/j.molcel.2018.10.042 ↗
69. 10.1038/s41467-021-22594-210.1038/s41467-021-22594-2 ↗
70. 10.1016/j.isci.2020.10181610.1016/j.isci.2020.101816 ↗
71. 10.1136/jitc-2020-00136910.1136/jitc-2020-001369 ↗
72. 10.1021/acsnano.2c0263410.1021/acsnano.2c02634 ↗
73. 10.1016/j.jconrel.2010.03.01610.1016/j.jconrel.2010.03.016 ↗
74. 10.1016/j.jconrel.2019.08.02810.1016/j.jconrel.2019.08.028 ↗
75. 10.1039/C4CS00177J10.1039/C4CS00177J ↗
76. 10.1007/s00204-009-0488-x10.1007/s00204-009-0488-x ↗
77. 10.1186/s13045-020-00939-610.1186/s13045-020-00939-6 ↗
78. 10.1021/bc980112410.1021/bc9801124 ↗
79. 10.1088/0957-4484/19/34/34560610.1088/0957-4484/19/34/345606 ↗
80. 10.1002/smll.20200599310.1002/smll.202005993 ↗
81. 10.1186/s12951-018-0382-x10.1186/s12951-018-0382-x ↗